Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 17/20 | 0.66 |
| ▸ | NRAS | P01111 | 15/20 | 0.66 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.66 |
| ▸ | CDK7 | P50613 | 2/20 | 0.66 |
| ▸ | CCNH | P51946 | 2/20 | 0.66 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | FLT4 | P35916 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.54 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19899931 | 0.87 | FLT3 (0.52) | FLT3NRASIRAK1PDGFRBCDK7 | |
| SCHEMBL24231714 | 0.87 | FLT3 (0.52) | FLT3NRASIRAK1PDGFRBCDK7 | |
| SCHEMBL24231497 | 0.86 | FLT3 (0.51) | FLT3NRASIRAK1PDGFRBCDK7 | |
| SCHEMBL24231434 | 0.84 | FLT3 (0.51) | FLT3NRASIRAK1PDGFRBCDK7 | |
| SCHEMBL24231884 | 0.84 | FLT3 (0.49) | FLT3NRASIRAK1PDGFRBCDK7 | |
| SCHEMBL19918240 | 0.83 | FLT3 (0.51) | FLT3NRASIRAK1PDGFRBCDK7 | |
| SCHEMBL24574511 | 0.83 | FLT3 (0.53) | FLT3NRASIRAK1PDGFRBCDK7 | |
| SCHEMBL24231782 | 0.82 | FLT3 (0.48) | FLT3NRASIRAK1PDGFRBCDK7 | |
| SCHEMBL24231686 | 0.82 | IRAK4 (0.62) | FLT3NRASIRAK1PDGFRBCDK7 | |
| SCHEMBL25764532 | 0.81 | FLT3 (0.53) | FLT3NRASIRAK1PDGFRBCDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-07-07 | — | — | US | disclosed |
| US-11254667-B2 | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200270242-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-08-27 | — | — | US | disclosed |
| US-20200199123-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | CHILDRENS HOSPITAL MED CT (US) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199123-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | IRAK1, IRAK2, IRAK3 | FLT3 63/4885NRAS 236/4885IRAK1 1/4885 |
| US-11254667-B2 | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors | IRAK1, IRAK4, FLT3 | FLT3 3/4885NRAS 121/4885IRAK1 1/4885 |
| US-20220213094-A1 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors | IRAK1, IRAK4, FLT3 | FLT3 3/4885NRAS 124/4885IRAK1 1/4885 |
| US-20200270242-A1 | COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS | VHL, ETV6, C5 | FLT3 549/4885NRAS 41/4885IRAK1 1164/4885 |
| US-11542261-B2 | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors | IRAK1, IRAK4, IRAK2 | FLT3 5/4885NRAS 239/4885IRAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.